CG Oncology, Inc. Common stock

CGONNASDAQ • USD
76.62 USD
↘ 8.16 (9.62%)🟢LIVE (AS OF 11:33 AM EST)
🟢Market: OPEN

CGON is currently priced at $76.62. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 16, 2026.

Open?$82.50
High?$86.06
Low?$73.13
Prev. Close?$84.78
Volume?1.3M
Avg. Volume?1.4M
VWAP?$77.54
Rel. Volume?0.91x
Bid / Ask
Bid?$73.00 × 100
Ask?$85.00 × 200
Spread?$12.00
Midpoint?$79.00
Valuation & Ratios
Market Cap?7.6B
Shares Out?89.3M
Float?68.6M
Float %?77.4%
P/E Ratio?N/A
P/B Ratio?7.64
EPS?-$2.66
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees
142
Market Cap
6.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
100
Momentum?
48
Short Sent.?
28
Piotroski F-Score?2/9Weak
Altman Z-Score?81.07Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?13.43%High
Short Interest?9.2M
Days to Cover?11.0
Free Float68.6M
Avg Daily Volume840.6K
Settlement Date2026-10-30
Financial Health
Current Ratio?21.70Strong
Quick Ratio?21.68Strong
Cash Ratio?0.61Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
24
7.64FAIR▾
P/S?
Peers
100
S&P
3
1,228.10HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-28.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
1,224.00HIGH▾
Returns & Efficiency
ROE?
S&P
7
-24.0%WEAK▾
ROA?
S&P
3
-22.7%WEAK▾
Cash Flow & Enterprise
FCF?$-189174000
Enterprise Value?$7.5B
Fundamentals ratios updated end of day